ZA200200691B - Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity. - Google Patents
Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity. Download PDFInfo
- Publication number
- ZA200200691B ZA200200691B ZA200200691A ZA200200691A ZA200200691B ZA 200200691 B ZA200200691 B ZA 200200691B ZA 200200691 A ZA200200691 A ZA 200200691A ZA 200200691 A ZA200200691 A ZA 200200691A ZA 200200691 B ZA200200691 B ZA 200200691B
- Authority
- ZA
- South Africa
- Prior art keywords
- optionally substituted
- substituted
- alkyl
- alkylamino
- atoms
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title claims description 21
- 150000004892 pyridazines Chemical class 0.000 title description 6
- 230000002401 inhibitory effect Effects 0.000 title description 3
- 125000003282 alkyl amino group Chemical class 0.000 claims description 124
- 125000000217 alkyl group Chemical group 0.000 claims description 124
- 125000004429 atom Chemical group 0.000 claims description 93
- 125000001072 heteroaryl group Chemical group 0.000 claims description 63
- 125000000623 heterocyclic group Chemical group 0.000 claims description 62
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 61
- 125000001424 substituent group Chemical group 0.000 claims description 59
- 229910052717 sulfur Inorganic materials 0.000 claims description 52
- 229910052760 oxygen Inorganic materials 0.000 claims description 46
- 125000003545 alkoxy group Chemical group 0.000 claims description 44
- 125000004414 alkyl thio group Chemical group 0.000 claims description 44
- 125000003107 substituted aryl group Chemical group 0.000 claims description 43
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 42
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 36
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 33
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 33
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 33
- 125000004432 carbon atom Chemical group C* 0.000 claims description 32
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 32
- 229910052736 halogen Inorganic materials 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 17
- -1 nitro, amidino, guanidino, mercapto, sulfo Chemical group 0.000 claims description 17
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 claims description 15
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 229940002612 prodrug Drugs 0.000 claims description 13
- 239000000651 prodrug Substances 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 125000006413 ring segment Chemical group 0.000 claims description 12
- 125000004423 acyloxy group Chemical group 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 10
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 10
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 10
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 7
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 101100241859 Mus musculus Oacyl gene Proteins 0.000 claims description 6
- 206010038923 Retinopathy Diseases 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 206010012441 Dermatitis bullous Diseases 0.000 claims description 4
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 206010015218 Erythema multiforme Diseases 0.000 claims description 4
- 206010034277 Pemphigoid Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 208000017442 Retinal disease Diseases 0.000 claims 5
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- IXMQNMIYTMPPQN-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)phthalazin-1-yl]methyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(CC=2C3=CC=CC=C3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 IXMQNMIYTMPPQN-UHFFFAOYSA-N 0.000 claims 2
- 206010036590 Premature baby Diseases 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- MJINNULTZJISHF-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-6-ylamino)phthalazin-1-yl]-2-pyridin-4-ylacetonitrile Chemical compound N=1N=C(NC=2C=C3SC=NC3=CC=2)C2=CC=CC=C2C=1C(C#N)C1=CC=NC=C1 MJINNULTZJISHF-UHFFFAOYSA-N 0.000 claims 1
- RWVWCWCFPGUTOK-UHFFFAOYSA-N 2-[4-(2,3-dihydro-1h-inden-5-ylamino)phthalazin-1-yl]-2-pyridin-4-ylacetonitrile Chemical compound N=1N=C(NC=2C=C3CCCC3=CC=2)C2=CC=CC=C2C=1C(C#N)C1=CC=NC=C1 RWVWCWCFPGUTOK-UHFFFAOYSA-N 0.000 claims 1
- FYHRHTSWTVJSDL-UHFFFAOYSA-N 4-(pyridin-4-ylmethyl)-n-(4-pyridin-4-yloxyphenyl)phthalazin-1-amine Chemical compound N=1N=C(NC=2C=CC(OC=3C=CN=CC=3)=CC=2)C2=CC=CC=C2C=1CC1=CC=NC=C1 FYHRHTSWTVJSDL-UHFFFAOYSA-N 0.000 claims 1
- HGZODYQRIITIQW-UHFFFAOYSA-N 4-[[4-(3-bromoanilino)phthalazin-1-yl]methyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(CC=2C3=CC=CC=C3C(NC=3C=C(Br)C=CC=3)=NN=2)=C1 HGZODYQRIITIQW-UHFFFAOYSA-N 0.000 claims 1
- UZQYWYITUJLZRE-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)phthalazin-1-yl]methyl]pyridine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=NC(C(=O)N)=CC(CC=2C3=CC=CC=C3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 UZQYWYITUJLZRE-UHFFFAOYSA-N 0.000 claims 1
- VRBILPUMSIISRB-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)phthalazin-1-yl]methyl]pyridine-2-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(CC=2C3=CC=CC=C3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 VRBILPUMSIISRB-UHFFFAOYSA-N 0.000 claims 1
- MLKSTRZTWVCYRC-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)phthalazin-1-yl]oxymethyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(COC=2C3=CC=CC=C3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 MLKSTRZTWVCYRC-UHFFFAOYSA-N 0.000 claims 1
- BSOULSOSONUODJ-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)phthalazin-1-yl]oxymethyl]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC(COC=2C3=CC=CC=C3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 BSOULSOSONUODJ-UHFFFAOYSA-N 0.000 claims 1
- XFDFYZZQEBZNGH-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)phthalazin-1-yl]oxymethyl]pyridine-2-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.C1=NC(C(=O)N)=CC(COC=2C3=CC=CC=C3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 XFDFYZZQEBZNGH-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- NWYVVOQTAAJFGB-UHFFFAOYSA-N CN.CS(O)(=O)=O.CS(O)(=O)=O Chemical compound CN.CS(O)(=O)=O.CS(O)(=O)=O NWYVVOQTAAJFGB-UHFFFAOYSA-N 0.000 claims 1
- 101100048435 Caenorhabditis elegans unc-18 gene Proteins 0.000 claims 1
- 101150034680 Lis-1 gene Proteins 0.000 claims 1
- 101150084844 PAFAH1B1 gene Proteins 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- CYVOMIZSBADRDI-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-5-yl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine Chemical compound N=1N=C(NC=2C=C3CCCC3=CC=2)C2=CC=CC=C2C=1CC1=CC=NC=C1 CYVOMIZSBADRDI-UHFFFAOYSA-N 0.000 claims 1
- NXQCPNSHDAECMC-UHFFFAOYSA-N n-(4-chlorophenyl)-4-(pyridin-3-ylmethoxy)phthalazin-1-amine Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1OCC1=CC=CN=C1 NXQCPNSHDAECMC-UHFFFAOYSA-N 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 230000004862 vasculogenesis Effects 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 2
- KWMLJOLKUYYJFJ-DIHCEYMBSA-N (2r,3s,4r,5r)-2,3,4,5,6,7-hexahydroxyheptanoic acid Chemical compound OCC(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-DIHCEYMBSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UHFFFAOYSA-N 3-phosphoglyceric acid Chemical compound OC(=O)C(O)COP(O)(O)=O OSJPPGNTCRNQQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- HXFOXFJUNFFYMO-BYPYZUCNSA-N N-alpha-acetyl-L-asparagine Chemical compound CC(=O)N[C@H](C(O)=O)CC(N)=O HXFOXFJUNFFYMO-BYPYZUCNSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000006629 Prosopis spicigera Nutrition 0.000 description 1
- 240000000037 Prosopis spicigera Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000648 angioblast Anatomy 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37132299A | 1999-08-10 | 1999-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200200691B true ZA200200691B (en) | 2003-10-29 |
Family
ID=23463486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200200691A ZA200200691B (en) | 1999-08-10 | 2002-01-25 | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1208096B1 (enExample) |
| JP (1) | JP2003506447A (enExample) |
| KR (1) | KR20020019969A (enExample) |
| CN (1) | CN1378543A (enExample) |
| AR (1) | AR025068A1 (enExample) |
| AT (1) | ATE265448T1 (enExample) |
| AU (1) | AU775237B2 (enExample) |
| BR (1) | BR0013113A (enExample) |
| CA (1) | CA2381621A1 (enExample) |
| CO (1) | CO5180637A1 (enExample) |
| DE (1) | DE60010280T2 (enExample) |
| ES (1) | ES2219382T3 (enExample) |
| IL (1) | IL147885A0 (enExample) |
| MX (1) | MXPA02001324A (enExample) |
| NO (1) | NO20020569L (enExample) |
| NZ (1) | NZ517087A (enExample) |
| PE (1) | PE20010494A1 (enExample) |
| WO (1) | WO2001010859A1 (enExample) |
| ZA (1) | ZA200200691B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6689883B1 (en) | 1999-09-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
| AR025752A1 (es) * | 1999-09-28 | 2002-12-11 | Bayer Corp | Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis |
| US7977333B2 (en) | 2000-04-20 | 2011-07-12 | Bayer Healthcare Llc | Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
| GB0111078D0 (en) | 2001-05-04 | 2001-06-27 | Novartis Ag | Organic compounds |
| EP1712234B1 (en) * | 2001-09-12 | 2009-01-28 | Novartis AG | Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment |
| CA2471314A1 (en) * | 2001-12-21 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| AU2003249369A1 (en) * | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| CN100372535C (zh) * | 2002-09-24 | 2008-03-05 | 诺瓦提斯公司 | 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途 |
| AU2003288034A1 (en) * | 2002-11-12 | 2004-06-03 | Novartis Ag | Treatment of mesothelioma |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| ES2470341T3 (es) | 2007-04-05 | 2014-06-23 | Amgen, Inc | Moduladores de la aurora cinasa y método de uso |
| PL2167549T3 (pl) | 2007-06-19 | 2013-03-29 | Rynel Inc | Materiały zawierające cząstki polimeru rozpuszczalnego w wodzie oraz sposoby ich wytwarzania i stosowania |
| AU2009226024B2 (en) | 2008-03-20 | 2012-07-12 | Amgen Inc. | Aurora kinase modulators and method of use |
| CA2732101C (en) * | 2008-08-04 | 2013-09-17 | Amgen Inc. | Aurora kinase modulators and methods of use |
| WO2010019473A1 (en) | 2008-08-14 | 2010-02-18 | Amgen Inc. | Aurora kinase modulators and methods of use |
| CN117355303A (zh) * | 2021-01-28 | 2024-01-05 | 佛罗里达大学研究基金会公司 | 化合物及其用于治疗神经退行性、退行性和代谢病症的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1293565A (en) * | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
| JPH03106875A (ja) * | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | １―（３―ピリジルメチル）フタラジン誘導体 |
| JPH0673022A (ja) * | 1992-08-27 | 1994-03-15 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
| EP0722936B1 (en) * | 1994-08-09 | 2004-05-19 | Eisai Co., Ltd. | Fused pyridazine compound |
| JP3919835B2 (ja) * | 1994-08-09 | 2007-05-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合ピリダジン系化合物 |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| ATE329596T1 (de) * | 1999-03-30 | 2006-07-15 | Novartis Pharma Gmbh | Phthalazinderivate zur behandlung von entzündlicher erkrankungen |
-
2000
- 2000-08-07 AR ARP000104073A patent/AR025068A1/es unknown
- 2000-08-08 IL IL14788500A patent/IL147885A0/xx unknown
- 2000-08-08 WO PCT/US2000/021579 patent/WO2001010859A1/en not_active Ceased
- 2000-08-08 PE PE2000000799A patent/PE20010494A1/es not_active Application Discontinuation
- 2000-08-08 DE DE60010280T patent/DE60010280T2/de not_active Expired - Lifetime
- 2000-08-08 MX MXPA02001324A patent/MXPA02001324A/es active IP Right Grant
- 2000-08-08 AU AU68954/00A patent/AU775237B2/en not_active Ceased
- 2000-08-08 CO CO00059237A patent/CO5180637A1/es unknown
- 2000-08-08 EP EP00957317A patent/EP1208096B1/en not_active Expired - Lifetime
- 2000-08-08 CN CN00814059A patent/CN1378543A/zh active Pending
- 2000-08-08 BR BR0013113-0A patent/BR0013113A/pt not_active IP Right Cessation
- 2000-08-08 KR KR1020027001797A patent/KR20020019969A/ko not_active Ceased
- 2000-08-08 NZ NZ517087A patent/NZ517087A/en unknown
- 2000-08-08 ES ES00957317T patent/ES2219382T3/es not_active Expired - Lifetime
- 2000-08-08 JP JP2001515668A patent/JP2003506447A/ja active Pending
- 2000-08-08 CA CA002381621A patent/CA2381621A1/en not_active Abandoned
- 2000-08-08 AT AT00957317T patent/ATE265448T1/de not_active IP Right Cessation
-
2002
- 2002-01-25 ZA ZA200200691A patent/ZA200200691B/en unknown
- 2002-02-05 NO NO20020569A patent/NO20020569L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU775237B2 (en) | 2004-07-22 |
| ES2219382T3 (es) | 2004-12-01 |
| NO20020569L (no) | 2002-04-10 |
| DE60010280D1 (de) | 2004-06-03 |
| MXPA02001324A (es) | 2002-07-22 |
| CO5180637A1 (es) | 2002-07-30 |
| ATE265448T1 (de) | 2004-05-15 |
| JP2003506447A (ja) | 2003-02-18 |
| NZ517087A (en) | 2004-05-28 |
| AU6895400A (en) | 2001-03-05 |
| CA2381621A1 (en) | 2001-02-15 |
| BR0013113A (pt) | 2002-04-30 |
| EP1208096A1 (en) | 2002-05-29 |
| IL147885A0 (en) | 2002-08-14 |
| AR025068A1 (es) | 2002-11-06 |
| EP1208096B1 (en) | 2004-04-28 |
| KR20020019969A (ko) | 2002-03-13 |
| NO20020569D0 (no) | 2002-02-05 |
| PE20010494A1 (es) | 2001-06-27 |
| CN1378543A (zh) | 2002-11-06 |
| WO2001010859A1 (en) | 2001-02-15 |
| DE60010280T2 (de) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beyer et al. | Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease | |
| KR102698413B1 (ko) | 헤테로방향족 거대환식 에터 화학치료제 | |
| Liang et al. | VEGF signal system: the application of antiangiogenesis | |
| ZA200205988B (en) | 2-amino-nicotinamide derivatives and their use as VEGF-receptor tyrosine kinase inhibitors. | |
| AU2001248324B2 (en) | Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy | |
| KR20170012562A (ko) | 글루타미나제 억제제를 사용하는 병용 요법 | |
| EP1107959A2 (en) | Quinazoline derivatives as medicaments | |
| KR20040004705A (ko) | 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도 | |
| KR20200080254A (ko) | 혈액학적 장애를 치료하기 위한 화합물 및 조성물 | |
| RU2016100363A (ru) | Композиции и способы лечения анемии | |
| CN102300568A (zh) | Hif-1蛋白积聚的抑制剂 | |
| AU2001248324A1 (en) | Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy | |
| US10745400B2 (en) | Inhibition of BMP signaling, compounds, compositions and uses thereof | |
| JP2022523358A (ja) | キナーゼ阻害剤 | |
| KR20190040302A (ko) | 글루타미나제 억제제와의 병용 요법 | |
| AU775237B2 (en) | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity | |
| JP2003535038A (ja) | 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物 | |
| Li et al. | Discovery of D25, a potent and selective MNK inhibitor for sepsis-associated acute spleen injury | |
| AU2017281980B2 (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| KR20090010112A (ko) | Ｍｔｏｒ 억제제 및 ｒａｆ 키나제 억제제를 포함하는 약학적 조합물 | |
| WO2022138944A1 (ja) | Ｓｗｉ／ｓｎｆ複合体機能異常がんの合成致死性に基づく治療法 | |
| SG175816A1 (en) | Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders | |
| CN101815514A (zh) | 磺酰基取代的2-磺酰基氨基苯甲酸n-苯基酰胺在治疗疼痛中的应用 | |
| WO2007054783A2 (en) | Compositions and methods for treating thrombocytopenia | |
| CN104788423B (zh) | 一种新的囊性纤维化跨膜传导调节因子抑制剂 |